The biotech IPO boom continues! Windward Bio (WWB.US) plans to raise 185 million USD, betting on an antibody drug administered once every six months.

智通财经APP reported that Swiss clinical-stage biotech company Windward Bio Group is seeking a valuation of up to 1 billion USD in its planned US initial public offering (IPO). On Monday, the company stated it plans to issue approximately 10.3 million shares at a price range of 16 to 18 USD per share, aiming to raise up to 185.3 million USD. The company will list on Nasdaq under the ticker symbol “WWB”.